Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients

LEUKEMIA

SPRINGERNATURE

1. Myeloma UK
2. National Institute of Health Biomedical Research Center at the Royal Marsden Hospital
3. Jacquelin ForbesNixon Fellowship
4. Cancer Research UK [C1298/A10410]
5. MRC [G0100132]
6. Institute of Cancer Research, London [A107]
7. Novartis
8. Schering Health Care
9. Chugai
10. Pharmion
11. Celgene
12. Ortho Biotech
13. Amgen
14. Merck Sharp Dohme
15. Clinical Trials Research Unit (CTRU) at Leeds
16. MRC [G0100132, MR/L006340/1] Funding Source: UKRI